ABVX Stock Overview
A clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ABIVAX Société Anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €8.50 |
| 52 Week High | €17.02 |
| 52 Week Low | €8.37 |
| Beta | 1.42 |
| 11 Month Change | -17.48% |
| 3 Month Change | -28.93% |
| 1 Year Change | -14.74% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 2.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABVX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.8% | 4.0% | 2.2% |
| 1Y | -14.7% | 18.3% | 32.6% |
Return vs Industry: ABVX underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: ABVX underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| ABVX volatility | |
|---|---|
| ABVX Average Weekly Movement | 5.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ABVX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ABVX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 62 | Marc M. de Garidel | www.abivax.com |
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.
ABIVAX Société Anonyme Fundamentals Summary
| ABVX fundamental statistics | |
|---|---|
| Market cap | US$541.97m |
| Earnings (TTM) | -US$186.21m |
| Revenue (TTM) | US$9.48m |
57.2x
P/S Ratio-2.9x
P/E RatioIs ABVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABVX income statement (TTM) | |
|---|---|
| Revenue | €9.03m |
| Cost of Revenue | €0 |
| Gross Profit | €9.03m |
| Other Expenses | €186.46m |
| Earnings | -€177.42m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.80 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,964.62% |
| Debt/Equity Ratio | 87.9% |
How did ABVX perform over the long term?
See historical performance and comparison